Corcept Therapeutics shares are approaching critical lows. What’s pressuring CORT?Appeals Court Upholds Ruling Against CorceptCorcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole. The appeals court agreed with the lower court that there was no proof doctors had used, or were likely to use, those specific regimens, especiall ...